bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S3 from Using DEPendency of association on the number of Top Hits (DEPTH) as a complementary tool to identify novel colorectal cancer susceptibility loci.
Authors: Lai John , Wong Chi Kuen , Schmidt Daniel F. , Kapuscinski Miroslaw K. , Alpen Karen , Maclnnis Robert J. , Buchanan Daniel D. , Win Aung K. , Figueiredo Jane C. , Chan Andrew T. , Harrison Tabitha A. , Hoffmeister Michael , White Emily , Le Marchand Loic , Pai Rish K. , Peters Ulrike , Hopper John L. , Jenkins Mark A. , Makalic Enes
Published: September 2024

Supplementary Table S3 shows the number of SNPs filtered out at each QC stage (according to Supplementary Table S2)
Supplementary Table S2 from HSA Adductomics Reveals Sex Differences in NHL Incidence and Possible Involvement of Microbial Translocation
Authors: Grigoryan Hasmik , Imani Partow , Sacerdote Carlotta , Masala Giovanna , Grioni Sara , Tumino Rosario , Chiodini Paolo , Dudoit Sandrine , Vineis Paolo , Rappaport Stephen M.
Published: September 2024

Supplementary Table S2: Cys34 and Lys525 adducts detected
Supplementary Figure S2 from HSA Adductomics Reveals Sex Differences in NHL Incidence and Possible Involvement of Microbial Translocation
Authors: Grigoryan Hasmik , Imani Partow , Sacerdote Carlotta , Masala Giovanna , Grioni Sara , Tumino Rosario , Chiodini Paolo , Dudoit Sandrine , Vineis Paolo , Rappaport Stephen M.
Published: September 2024

Supplementary Figure S2: Plots of ln(case/matched-control fold change) versus time to diagnosis (ttd) in days from recruitment for adduct features selected for MALES and FEMALES
Supplementary Figure S1 from HSA Adductomics Reveals Sex Differences in NHL Incidence and Possible Involvement of Microbial Translocation
Authors: Grigoryan Hasmik , Imani Partow , Sacerdote Carlotta , Masala Giovanna , Grioni Sara , Tumino Rosario , Chiodini Paolo , Dudoit Sandrine , Vineis Paolo , Rappaport Stephen M.
Published: September 2024

Supplementary Figure S1: Ensemble of classification models for selection of adduct features associated with NHL incidence
Table S3 from Predicted proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility
Authors: Gregga Isabelle , Pharoah Paul DP. , Gayther Simon A. , Manichaikul Ani , Im Hae Kyung , Kar Siddhartha P. , Schildkraut Joellen M. , Wheeler Heather E.
Published: September 2024

Table S3. PWAS meta-FDR<0.05 proteins with ovarian cancer associations.
Supplementary Figure S1 from Predicted proteome association studies of breast, prostate, ovarian, and endometrial cancers implicate plasma protein regulation in cancer susceptibility
Authors: Gregga Isabelle , Pharoah Paul DP. , Gayther Simon A. , Manichaikul Ani , Im Hae Kyung , Kar Siddhartha P. , Schildkraut Joellen M. , Wheeler Heather E.
Published: September 2024

Supplementary Figure S1: Workflow illustrating the methods.
Supplementary Figure S4 from Characteristics of Cancer Epidemiology Studies that Employ Metabolomics: A Scoping Review
Authors: Yu Catherine T. , Farhat Zeinab , Livinski Alicia A. , Loftfield Erikka , Zanetti Krista A.
Published: September 2024

Supplementary Figure S4 shows bar graph displaying distribution of metabolomic epidemiology studies of cancer by number of cancer cases recruited.
Supplementary Figure S2 from Characteristics of Cancer Epidemiology Studies that Employ Metabolomics: A Scoping Review
Authors: Yu Catherine T. , Farhat Zeinab , Livinski Alicia A. , Loftfield Erikka , Zanetti Krista A.
Published: September 2024

Supplementary Figure S2 shows geographic distribution of participant recruitment for metabolomic epidemiology studies of cancer.
Supplemental Table 1 from Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials
Authors: Streck Joanna M. , Lee Ju-Whei , Walter Angela Wangari. , Rosen Rachel L. , Gareen Ilana F. , Kircher Sheetal Mehta. , Herman Benjamin A. , Carlos Ruth C. , Kumar Shaji , Mayer Ingrid A. , Saba Nabil F. , Fenske Timothy S. , Neal Joel W. , Atkins Michael B. , Hodi F Stephen. , Kyriakopoulos Christos E. , Tempany Clare , Shanafelt Tait D. , Wagner Lynne I. , Land Stephanie R. , Park Elyse R. , Ostroff Jamie S.
Published: September 2024

Supplemental Table 1 shows cancer types, patient accrual and survey completion rates for parent trials
Supplementary Table 4 from Patterns of evidence-based care for the diagnosis, staging, and first-line treatment of breast cancer by race-ethnicity: a SEER-Medicare study
Authors: Herbach Emma L. , Nash Sarah H. , Lizarraga Ingrid M. , Carnahan Ryan M. , Wang Kai , Ogilvie Amy C. , Curran Michaela , Charlton Mary E.
Published: September 2024

Supplementary Table 4 shows a sensitivity analysis: rate ratios for all outcomes adjusted for all covariates except marital status and low-income subsidy.
Supplementary Table 1 from Patterns of evidence-based care for the diagnosis, staging, and first-line treatment of breast cancer by race-ethnicity: a SEER-Medicare study
Authors: Herbach Emma L. , Nash Sarah H. , Lizarraga Ingrid M. , Carnahan Ryan M. , Wang Kai , Ogilvie Amy C. , Curran Michaela , Charlton Mary E.
Published: September 2024

Supplementary Table 1 provides detailed definitions for all study variables, including billing codes and data sources used.
Supplementary Table S3 from Socioeconomic status at birth and breast tissue composition in adolescence and adulthood
Authors: Kehm Rebecca D. , Lilge Lothar , Walter E Jane , White Melissa , Herbstman Julie B. , Perera Frederica P. , Miller Rachel L. , Terry Mary Beth , Tehranifar Parisa
Published: September 2024

Supplementary Table S3 shows the characteristics of adult women by maternal education at birth in the Columbia Breast Cancer and the Environment Research Program (Columbia-BCERP) Study, n = 160.
Supplementary Table S4 from Prediagnostic prescription antibiotics use and survival in colorectal cancer patients: A Swedish national register-based study
Authors: Lu Sai San Moon , Rutegård Martin , Ahmed Maghfoor , Häggström Christel , Gylfe Åsa , Harlid Sophia , Van Guelpen Bethany
Published: September 2024

Supplementary Table S4: Characteristics of stage IV colorectal cancer patients
Supplementary Figure 1 from Changes in geographic variation and socioeconomic inequalities in esophageal cancer mortality in China, 1973-2017
Authors: Ran Xianhui , Zheng Rongshou , Zeng Hongmei , Zhang Siwei , Sun Kexin , Han Bingfeng , Wang Shaoming , Chen Ru , Li Li , Wei Wenqiang , He Jie
Published: September 2024

Supplementary Figure 1 shows the geographic distribution and population coverage of 782 counties included in final analyses, along with the population density of China.
Supplementary Table S1 from Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes
Authors: Chen Ji-Qing , Salas Lucas A. , Wiencke John K. , Koestler Devin C. , Molinaro Annette M. , Andrew Angeline S. , Seigne John D. , Karagas Margaret R. , Kelsey Karl T. , Christensen Brock C.
Published: September 2024

Supplementary Table S1: Cox proportional hazards multivariable models for age acceleration of 601 NMIBC patients
Supplementary Table S4 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: September 2024

Supplementary Table S4. Multivariate MR estimates of direct causal effects of traits on lung cancer individually conditioned on genetically influenced smoking, alcohol use, socioeconomic status, and educational attainment.
Supplementary Figure S1 from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: September 2024

Supplementary Figure S1. IVW multivariate MR estimation of direct impact of traits on lung adenocarcinoma development, conditioned on smoking (pack years per lifespan), income, and years of schooling.
Supplementary Table 3 from The Association of Kidney Function and Inflammatory Biomarkers with Epithelial Ovarian Cancer Risk
Authors: Hathaway Cassandra A. , Townsend Mary K. , Sklar Elliot M. , Thomas-Purcell Kamilah B. , Terry Kathryn L. , Trabert Britton , Tworoger Shelley S.
Published: September 2024

Hazard ratios (HR) and 95% confidence intervals (95%CI) of kidney related markers measured in urine and ovarian cancer risk by histological subtype in the UK Biobank.
Supplementary Figure S1 from Sex-specific associations between adiponectin and leptin signaling and pancreatic cancer survival
Authors: Babic Ana , Wang Qiao-Li , Lee Alice A. , Yuan Chen , Rifai Nader , Luo Juhua , Tabung Fred K. , Shadyab Aladdin , Wactawski-Wende Jean , Saquib Nazmus , Kim Jihye , Kraft Peter , Sesso Howard D. , Buring Julie E. , Giovannucci Edward L. , Manson JoAnn E. , Stampfer Meir J. , Ng Kimmie , Fuchs Charles S. , Wolpin Brian M.
Published: September 2024

Association between leptin levels and pancreatic cancer mortality using spline regression.
Data from Associations of post-diagnosis lifestyle with prognosis in women with invasive breast cancer
Authors: Troeschel Alyssa N. , Hartman Terryl J. , McCullough Lauren E. , Ergas Isaac J. , Collin Lindsay J. , Kwan Marilyn L. , Ambrosone Christine B. , Flanders W Dana , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Wang Ying , Valice Emily , Kushi Lawrence H.
Published: September 2024

Abstract
Background: Lifestyle habits can impact breast cancer (BC) development, but its impact on BC prognosis remains unclear. We investigated associations of post-diagnosis lifestyle with mortality and recurrence in 1,964 women with invasive BC enrolled in the Kaiser Permanente Northern California Pathways Study shortly after diagnosis with lifestyle information at baseline (2005–2013) and the 2-year follow-up.

Methods: We calculated a post-diagnosis lifestyle score (range: 0–18) based on 9 diet, physical activity (PA), and body weight recommendations from the American Cancer Society/American Society of Clinical Oncology (ACS/ASCO) using follow-up data (body weight also included baseline data); higher scores indicate greater guideline concordance. Similarly, we calculated a pre-diagnosis lifestyle score using baseline data to investigate pre- to post-diagnosis changes. We estimated hazard ratios (HR) and 95% CIs using Cox proportional hazard models, with follow-up through December 2018 (observing 290 deaths and 176 recurrences).

Results: The 2-year post-diagnosis lifestyle score was inversely associated with all-cause mortality (ACM) (HR per 2-point increase=0.90, 95%CI: 0.82, 0.98), and BC-mortality (HR=0.79, 95%CI: 0.67, 0.95), but not recurrence. Relative to women who maintained low concordance with recommendations at both time points, women who maintained high concordance had a lower risk of ACM (HR=0.61, 95%CI: 0.37, 1.03). Improved concordance with some specific recommendations (particularly PA) may be associated with a lower hazard of ACM (HRPA=0.52, 95%CI: 0.35, 0.78).

Conclusions: Results suggest that women with BC may benefit from a post-diagnosis lifestyle aligned with ACS/ASCO guidelines.

Impact: This information may potentially guide lifestyle recommendations for BC survivors to reduce mortality risk.
Data from Dying to Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era
Authors: Klein Eric A. , Madhavan Sarina , Beer Tomasz M. , Bettegowda Chetan , Liu Minetta C. , Hartman Anne-Renee , Hackshaw Allan
Published: September 2024

Abstract
Cancer is a significant burden worldwide that adversely impacts life expectancy, quality of life, health care costs and workforce productivity. While currently recommended screening tests for individual cancers reduce mortality, they detect only a minority of all cancers and sacrifice specificity for high sensitivity, resulting in a high cumulative rate of false positives. Blood-based multicancer early detection tests (MCEDs) based on next generation sequencing and other technologies hold promise for broadening the number of cancer types detected in screened populations and hope for reducing cancer mortality. The promise of this new technology to improve cancer detection rates and make screening more efficient at the population level demands the development of novel trial designs that accelerate clinical adoption. Carefully designed clinical trials are needed to address these issues.
Data from Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and outcomes
Authors: Kaur Mandeep , Patterson Anne , Molina-Vega Julissa , Rothschild Harriet , Clelland Elle , Ewing Cheryl A. , Mujir Firdows , Esserman Laura J. , Olopade Olufunmilayo I. , Mukhtar Rita A.
Published: September 2024

Abstract
Background: While investigators have shown associations between socioeconomic status (SES) and outcomes in breast cancer, there is a paucity of such data for invasive lobular carcinoma (ILC), the second most common type of breast cancer. Herein we evaluated the relationship between SES with tumor features and outcomes in stage I-III patients with ILC.

Methods: We analyzed a prospectively maintained institutional ILC database and utilized the Area Deprivation Index (ADI) to determine neighborhood adversity, an indicator of SES. We used Cox proportional hazards models in Stata 17.0 to evaluate relationships between ADI quintile (Q), race, body mass index (BMI), clinicopathologic features, treatment type, and event-free survival (EFS).

Results: Of 804 patients with ILC, 21.4% lived in neighborhoods classified as ADI Q1 (least resource-deprived) and 19.7% in Q5 (most resource-deprived). Higher deprivation was significantly associated with larger tumor size (3.6 cm in Q5 versus 3.1 cm in Q1), increased presence of lymphovascular invasion (8.9% in Q5 versus 6.7% in Q1), and decreased use of adjuvant endocrine therapy (67.1% in Q5 versus 73.6% in Q1). On multivariable analysis, tumor size, receptor subtypes, and omission of adjuvant endocrine therapy were associated with reduced EFS.

Conclusions: These data show that patients with ILC and higher ADI experience more aggressive tumors and differences in treatment. More data evaluating the complex relationships between these factors is needed to optimize outcomes for patients with ILC, regardless of SES.

Impact: ADI is associated with differences in patients with ILC.
Data from Relationship between ABO blood group alleles and pancreatic cancer is modulated by secretor (FUT2) genotype, but not Lewis antigen (FUT3) genotype
Authors: Kim Jihye , Yuan Chen , Amundadottir Laufey T. , Wolpin Brian M. , Klein Alison P. , Risch Harvey A. , Kraft Peter
Published: September 2024

Abstract
Background: In western populations, Pancreatic Ductal Adenocarcinoma (PDAC) risk has been found to be greater among individuals with non-O blood types than those with O blood type. However, the association has not been fully evaluated with respect to FUT2 (determining secretor status) and FUT3 (determining Lewis antigens) status, two biologically important genes in the expression of ABO blood groups with PDAC.

Methods: We examined interactions in data from 8,027 cases and 11,362 controls in large pancreatic cancer consortia (PanScan I-III and PanC4) by utilizing genetic variants to predict ABO blood groups (rs505922 and rs8176746), secretor status (rs601338), and Lewis antigens (rs812936, rs28362459, and rs3894326). Multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) of the risk of PDAC adjusted for age and sex. We examined multiplicative interactions of ABO with secretor status and Lewis group by considering each product term between ABO and secretor and between ABO and Lewis group individually.

Results: We found that the increased risk associated with non-O blood groups was somewhat stronger among secretors than non-secretors (ORs 1.28 [95% CI: 1.15-1.42] and 1.17 [95% CI: 1.03-1.32] respectively; interaction p-value = 0.002). We did not find any interactions between ABO and Lewis antigens.

Conclusions: Our large consortia data provide evidence of effect modification in the association between non-O blood type and pancreatic cancer risk by secretor status.

Impact: Our results indicate that the association between ABO blood type and PDAC risk may vary by secretor status, but not by Lewis antigens.
Data from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Authors: Edwards Kathryn C. , Khan Asia , Sharma Eva , Wang Lanqing , Feng June , Blount Benjamin C. , Sosnoff Connie S. , Smith Danielle M. , Goniewicz Maciej L. , Pearson Jennifer , Villanti Andrea C. , Delnevo Cristine D. , Bover Manderski Michelle T. , Hatsukami Dorothy K. , Niaura Raymond , Everard Colm , Kimmel Heather L. , Duffy Kara , Rostron Brian L. , Del Valle-Pinero Arseima Y. , van Bemmel Dana M. , Stanton Cassandra A. , Hyland Andrew
Published: September 2024

Abstract
Background: Sex and racial/ethnic identity specific cut-points for validating tobacco use using Wave 1 (W1) of the PATH Study were published in 2020. The current study establishes predictive validity of the W1 (2014) urinary cotinine and Total Nicotine Equivalents-2 (TNE-2) cut-points on estimating Wave 4 (W4; 2017) tobacco use.
Methods: For exclusive and polytobacco cigarette use, weighted prevalence estimates based on W4 self-report alone and with exceeding the W1 cut-point were calculated to identify the percentage missed without biochemical verification. Sensitivity and specificity of W1 cut-points on W4 self-reported tobacco use status were examined. Receiver Operating Characteristic curves were used to determine the optimal W4 cut-points to distinguish P30D users from non-users, and evaluate if the cut-points significantly differed from W1.
Results: Agreement between W4 self-reported use and exceeding the W1 cut-points was high overall and when stratified by demographic subgroups (0.7- 4.4% of use was missed if relying on self-report alone). The predictive validity of using the W1 cut-points to classify exclusive cigarette and polytobacco cigarette use at W4 was high (>90% sensitivity and specificity, except among polytobacco Hispanic smokers). Cut-points derived using W4 data did not significantly differ from the W1 derived cut-points (e.g., W1 exclusive= 40.5 ng/mL cotinine [95% CI: 26.1-62.8], W4 exclusive = 29.9 ng/ml cotinine [95% CI: 13.5-66.4]), among most demographic subgroups.
Conclusion: The W1 cut-points remain valid for biochemical verification of self-reported tobacco use in W4.
Impact: Findings from can be used in clinical and epidemiological studies to reduce misclassification of cigarette smoking status.
Data from Hospitalisations and Cost of Inpatient Care for Physical Diseases in Survivors of Childhood Cancer in Western Australia: a Longitudinal Matched Cohort Study.
Authors: Abdalla Tasnim , Walwyn Thomas , White Daniel , Choong Catherine S. , Bulsara Max , Preen David B. , Ohan Jeneva L.
Published: September 2024

Abstract
Background. The long-term effects of childhood cancer are unclear in the Australian context. We examined hospitalisation trends for physical diseases and estimated the associated inpatient care costs in all 5-year childhood cancer survivors (CCS) diagnosed in Western Australia (WA) from 1982-2014.

Methods. Hospitalisation records for 2,938 CCS and 24,792 comparisons were extracted from 1987- 2019 (median follow-up=12 years, min=1, max=32). The adjusted hazard ratio (aHR) of hospitalisation with 95% confidence intervals (CI) was estimated using the Andersen-Gill model for recurrent events. The cumulative burden of hospitalisations over time was assessed using the mean cumulative count method. The adjusted mean cost of hospitalisation was estimated using the generalised linear models.

Results. We identified a higher risk of hospitalisation for all-cause (aHR=2.0, 95%CI= 1.8-2.2) physical disease in CCS than comparisons, with the highest risk for subsequent malignant neoplasms (aHR=15.0, 95%CI 11.3-19.8) and blood diseases (aHR=6.9, 95%CI 2.6-18.2). Characteristics associated with higher hospitalisation rates included female gender, diagnosis with bone tumours, cancer diagnosis age between 5-9 years, multiple childhood cancer diagnoses, multiple comorbidities, higher deprivation, increased remoteness, and Indigenous status. The difference in the mean total hospitalisation costs for any disease was significantly higher in survivors than comparisons (publicly funded $11,483 United States Dollar, p<0.05).

Conclusions. The CCS population face a significantly higher risk of physical morbidity and higher cost of hospital-based care than the comparisons.

Impact. Our study highlights the need for long-term follow-up healthcare services to prevent disease progression and mitigate the burden of physical morbidity on patients and hospital services.
Data from Characteristics of Cancer Epidemiology Studies that Employ Metabolomics: A Scoping Review
Authors: Yu Catherine T. , Farhat Zeinab , Livinski Alicia A. , Loftfield Erikka , Zanetti Krista A.
Published: September 2024

Abstract
An increasing number of cancer epidemiology studies use metabolomics assays. This scoping review characterizes trends in the literature in terms of study design, population characteristics, and metabolomics approaches and identifies opportunities for future growth and improvement. We searched PubMed/MEDLINE, Embase, Scopus, and Web of Science: Core Collection databases and included research articles that used metabolomics to primarily study cancer, contained minimum 100 cases in each main analysis stratum, used an epidemiological study design, and were published in English from 1998–June 2021. 2048 articles were screened of which 314 full texts were further assessed resulting in 77 included articles. The most well-studied cancers were colorectal (19.5%), prostate (19.5%), and breast (19.5%). Most studies used a nested case-control design to estimate associations between individual metabolites and cancer risk and a liquid chromatography-tandem mass spectrometry untargeted or semi-targeted approach to measure metabolites in blood. Studies were geographically diverse, including countries in Asia, Europe, and North America; 27.3% of studies reported on participant race, majority reporting White participants. Most studies (70.2%) included fewer than 300 cancer cases in their main analysis. This scoping review identified key areas for improvement, including needs for standardized race and ethnicity reporting, more diverse study populations, and larger studies.
Data from Heritable Traits and Lung Cancer Risk: A Two-Sample Mendelian Randomization Study
Authors: Pettit Rowland W. , Byun Jinyoung , Han Younghun , Ostrom Quinn T. , Coarfa Cristian , Bondy Melissa L. , Amos Christopher I.
Published: September 2024

Abstract
Introduction: Lung cancer is a complex polygenic disorder. Analysis with Mendelian randomization (MR) allows for genetically predicted risks to be estimated between exposures and outcomes.

Methods: We analyzed 345 heritable traits from the United Kingdom biobank and estimated their associated effects on lung cancer outcomes using two sample MR. In addition to estimating effects with overall lung cancer, adenocarcinoma, small cell and squamous cell lung cancers, we performed conditional effect modeling with MVMR and the traits of alcohol use, smoking initiation, average pre-tax income, and educational attainment.

Results: Univariate MR provided evidence for increased age at first sexual intercourse (OR = 0.55, p = 6.15x10-13), educational attainment (OR = 0.24, p = 1.07x10-19), average household income (OR = 0.58, p = 7.85x10-05), and alcohol usually taken with meals (OR = 0.19, p = 1.06x10-06) associating with decreased odds of overall lung cancer development. In contrast a lack of additional educational attainment (OR = 8.00, p = 3.48x10-12), body mass index (OR = 1.28, p = 9.00x10-08), pack years smoking as a proportion of life span (OR = 9.93, p = 7.96x10-12), and weekly beer intake (OR = 3.48, p = 4.08x10-07) were associated with an increased risk of overall lung cancer development.

Conclusions: Many heritable traits associated with an increased or inverse risk of lung cancer development. Effects vary based on histological subtype and conditional third trait exposures.

Impact: We identified several heritable traits and presented their genetically predictable impact on lung cancer development, providing valuable insights for consideration.
Data from Dietary fish and n-3 polyunsaturated fatty acid consumption, and renal cell carcinoma risk in Japan: The Japan Public Health Center-based Prospective Study
Authors: Takahashi Michiko , Sobue Tomotaka , Zha Ling , Kitamura Tetsuhisa , Iwasaki Motoki , Inoue Manami , Yamaji Taiki , Tsugane Shoichiro , Sawada Norie
Published: September 2024

Abstract
Background: Previous epidemiological studies found inconsistent associations between fish consumption and renal cell carcinoma (RCC). Although the consumption of n-3 polyunsaturated fatty acids (n-3 PUFA) was reported to protect against the development of some types of cancer, little is known regarding its association with RCC.
Methods: We investigated the association between fish and n-3 PUFA consumption and RCC risk using the Japan Public Health Center-based Prospective Study. We examined data from 84,063 eligible Japanese participants aged 45–74 years who responded to a validated food frequency questionnaire for Cohort I in 1995 and Cohort II in 1998. The participants were followed-up until 2013. HRs and 95% confidence intervals (CIs) were estimated using a multivariable-adjusted Cox proportional hazard model, and the exposure level was categorized into quartiles.
Results: Among the 1,272,298 person-years of follow-up, 262 cases of newly diagnosed RCC were identified. The multivariate-adjusted HRs for the highest vs. lowest quartile of fish, including shellfish, were [HR=1.43, 95% CI (0.98–2.07)] and the individual marine n-3 PUFAs were [HR=1.56, 95% CI (1.07–2.28) Ptrend=0.09] for eicosapentenoic acid, [HR=1.81, 95% CI (1.27–2.59) Ptrend=0.01] for docosapentaenoic acid, and [HR=1.56, 95% CI (1.07–2.27) Ptrend=0.09] for docosahexaenoic acid. RCC were further categorized based on diagnosis methods and cancer stage, and the positive correlation did not change substantially.
Conclusion: We demonstrated that high consumption of n-3PUFA is associated with RCC risk.
Impact: The positive association between n-3 PUFA and RCC risk was observed in Japanese who consume higher amounts of fish than Western populations.
Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Ramakrishnan Geethakumari Praveen Ramakrishnan. , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: September 2024

Supplemental Figure 2. MEDI-570 effects on lymphocyte and leukocyte populations. Baseline-normalized, absolute counts (ABS) of circulating cell populations were plotted on study days 1, 7, 14 and 21 from patients enrolled in each dose group as indicated.
A)Total CD3+CD8+ cytotoxic T cells B) CD14+ monocytes C) CD3-CD56+ and/or CD16+ NK cells D) CD3-CD19+ B cells.
Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma
Authors: Chavez Julio C. , Foss Francine M. , William Basem M. , Brammer Jonathan E. , Smith Sonali M. , Prica Anca , Zain Jasmine M. , Tuscano Joseph M. , Shah Harsh , Mehta-Shah Neha , Ramakrishnan Geethakumari Praveen Ramakrishnan. , Wang Ben X. , Zantinge Stephanie , Wang Lisa , Zhang Ling , Boutrin Anmarie , Zhao Weiguang , Cheng Lily , Standifer Nathan , Hewitt Lisa , Enowtambong Enowmpey , Shao Weiping , Sharma Shringi , Carlesso Gianluca , Moscow Jeffrey A. , Siu Lillian L.
Published: September 2024

Supplemental Figure 1. CD4 count recovery after end of treatment (by local site collection)
Supplemental Tables 1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

File containing supplemental data
Figure S7 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

Supplemental Figure S7. CLDN6 expression in ovarian and endometrial cancer tissue samples.
Figure S5 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

Supplemental Figure S5: Induction of apoptosis following 48 hr treatment of CLDN6 positive OVCA429 and CLDN6 negative M202 cells with a range of concentrations (50 μg/ml - 0.3658μg/ml) of CLDN6-23-ADC compared to control IgG ADC.
Figure S1 from Preclinical Efficacy of the Antibody-Drug-Conjugate CLDN6-23-ADC for the Treatment of CLDN6 Positive Solid Tumors
Authors: McDermott Martina S.J. , O'Brien Neil A. , Hoffstrom Benjamin , Gong KeWei , Lu Ming , Zhang Jun , Luo Tong , Liang Min , Jia Weiping , Hong Jenny , Chau Kevin , Davenport Simon , Xie Bin , Press Michael F. , Panayiotou Richard , Handly-Santana Abram , Brugge Joan S. , Presta Leonard , Glaspy John , Slamon Dennis J.
Published: September 2024

Supplemental Figure S1: Expression of CLDN6 by transcript in the GTEX dataset of normal tissue samples.
Supplementary Table S1 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
Authors: Grant Michael J. , Aredo Jacqueline V. , Starrett Jacqueline H. , Stockhammer Paul , van Alderwerelt van Rosenburgh Iris K. , Wurtz Anna , Piper-Valillo Andrew J. , Piotrowska Zofia , Falcon Christina , Yu Helena A. , Aggarwal Charu , Scholes Dylan , Patil Tejas , Nguyen Christina , Phadke Manali , Li Fang-yong , Neal Joel , Lemmon Mark A. , Walther Zenta , Politi Katerina , Goldberg Sarah B.
Published: September 2024

Supplementary Table S1. Descriptive analysis of patient characteristics and outcomes for those with tumors harboring uncommon exon 19 deletions treated with osimertinib. Each variant represented ≤2.5% of the study cohort. Patients with + for “Smoking History” are those with either a prior or current smoking history. PFS=Progression free survival; OS= Overall survival;  denotes patients who have not yet experienced an event for a time to event endpoint.
Supplementary Figure S2 from Efficacy of osimertinib in patients with lung cancer positive for uncommon EGFR exon 19 deletion mutations
Authors: Grant Michael J. , Aredo Jacqueline V. , Starrett Jacqueline H. , Stockhammer Paul , van Alderwerelt van Rosenburgh Iris K. , Wurtz Anna , Piper-Valillo Andrew J. , Piotrowska Zofia , Falcon Christina , Yu Helena A. , Aggarwal Charu , Scholes Dylan , Patil Tejas , Nguyen Christina , Phadke Manali , Li Fang-yong , Neal Joel , Lemmon Mark A. , Walther Zenta , Politi Katerina , Goldberg Sarah B.
Published: September 2024

Supplementary Figure S2. Progression Free Survival for patients with tumors harboring select exon 19 deletions treated with first-line osimertinib. The point estimate for median progression free survival associated with each mutation is listed to the right of the figure legend.
Figure S9 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Authors: Bidkar Anil P. , Wang Sinan , Bobba Kondapa Naidu. , Chan Emily , Bidlingmaier Scott , Egusa Emily A. , Peter Robin , Ali Umama , Meher Niranjan , Wadhwa Anju , Dhrona Suchi , Dasari Chandrashekhar , Beckford-Vera Denis , Su Yang , Tang Ryan , Zhang Li , He Jiang , Wilson David M. , Aggarwal Rahul , VanBrocklin Henry F. , Seo Youngho , Chou Jonathan , Liu Bin , Flavell Robert R.
Published: September 2024

Figure S9: Histology evaluation of the healthy tissues for long-term (117 days) toxicity analysis. Hematoxylin and Eosin (H&E) staining of spleen, liver, lungs, heart, and bone samples show no toxicity at 0.25 µCi or 0.5 µCi doses of [225Ac]DOTA-YS5. Scale bar: 20 µm
Figure S4 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Authors: Bidkar Anil P. , Wang Sinan , Bobba Kondapa Naidu. , Chan Emily , Bidlingmaier Scott , Egusa Emily A. , Peter Robin , Ali Umama , Meher Niranjan , Wadhwa Anju , Dhrona Suchi , Dasari Chandrashekhar , Beckford-Vera Denis , Su Yang , Tang Ryan , Zhang Li , He Jiang , Wilson David M. , Aggarwal Rahul , VanBrocklin Henry F. , Seo Youngho , Chou Jonathan , Liu Bin , Flavell Robert R.
Published: September 2024

Figure S4: Gamma energy spectra of the tumor, blood, kidneys, and bone showing the intensities of the 213Bi and 221Fr peaks. As compared to the equilibrium gamma energy spectra of [225Ac]DOTA-YS5, increased intensity of the 213Bi was observed in kidney samples.
Figure S1 from Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
Authors: Bidkar Anil P. , Wang Sinan , Bobba Kondapa Naidu. , Chan Emily , Bidlingmaier Scott , Egusa Emily A. , Peter Robin , Ali Umama , Meher Niranjan , Wadhwa Anju , Dhrona Suchi , Dasari Chandrashekhar , Beckford-Vera Denis , Su Yang , Tang Ryan , Zhang Li , He Jiang , Wilson David M. , Aggarwal Rahul , VanBrocklin Henry F. , Seo Youngho , Chou Jonathan , Liu Bin , Flavell Robert R.
Published: September 2024

Figure S1: Immunohistochemical staining for PSMA expression on tissue section from patient-derived xenografts. Scale bar = 200 µm
Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Tables

Supplementary Table 1: Patient and tumor sample information
Supplementary Table 2: Tumor mutation burden
Supplementary Table 3: Unfiltered whole exome sequencing mutation analysis
Supplementary Table 4: Filtered whole exome sequencing mutation analysis
Supplementary Table 5: Immunohistochemistry scores of tumors
Supplementary Table 6: FACS panel for PBMC analysis
Supplementary Table 7: Geometric mean fluorescence intensity (GMFI) from PBMC FACS
Supplementary Table 8: Representativeness of Study Participants
Figure S7 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 7: Representative IHC staining of additional PD and SD tumors in pre-treatment and post-treatment timepoint from additional patients.
Figure S1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
Authors: Jang H. Josh , Hostetter Galen , MacFarlane Alexander W. , Madaj Zachary , Ross Eric A. , Hinoue Toshinori , Kulchycki Justin R. , Burgos Ryan S. , Tafseer Mahvish , Alpaugh R. Katherine , Schwebel Candice L. , Kokate Rutika , Geynisman Daniel M. , Zibelman Matthew R. , Ghatalia Pooja , Nichols Peter W. , Chung Woonbok , Madzo Jozef , Hahn Noah M. , Quinn David I. , Issa Jean-Pierre J. , Topper Michael J. , Baylin Stephen B. , Shen Hui , Campbell Kerry S. , Jones Peter A. , Plimack Elizabeth R.
Published: September 2024

Supplementary Figure 1: Patient recruitment and sample collection overview.
Supplementary Figure S4 from A tumor suppressive-molecular axis EP300/circRERE/miR-6837-3p/MAVS activates type I interferon pathway and anti-tumor immunity to suppress colorectal cancer
Authors: Ding Nan , You A-Bin , Yang Hu , Hu Guo-sheng , Lai Chun-Ping , Liu Wen , Ye Feng
Published: September 2024

Figure S4: miR-6837-3p promotes CRC cell growth.
Supplemental Figure 4 from Myosin light chain kinase inhibition potentiates the anti-tumor effects of avapritinib in PDGFRA D842V-mutant gastrointestinal stromal tumor
Authors: Rossi Ferdinand , Liu Mengyuan , Tieniber Andrew , Etherington Mark S. , Hanna Andrew , Vitiello Gerardo A. , Param Nesteene J. , Do Kevin , Wang Laura , Antonescu Cristina R. , Zeng Shan , Zhang Jennifer Q. , DeMatteo Ronald P.
Published: September 2024

Supplemental Figure 4.
Supplementary Table S1 from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Authors: Liam Chong Kin , Ahmad Azura Rozila , Hsia Te-Chun , Zhou Jianying , Kim Dong-Wan , Soo Ross Andrew. , Cheng Ying , Lu Shun , Shin Sang Won , Yang James Chi-Hsin , Zhang Yiping , Zhao Jun , Berghoff Karin , Bruns Rolf , Johne Andreas , Wu Yi-Long
Published: September 2024

Demographic data of all individuals enrolled
Supplementary PLS from Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Authors: Liam Chong Kin , Ahmad Azura Rozila , Hsia Te-Chun , Zhou Jianying , Kim Dong-Wan , Soo Ross Andrew. , Cheng Ying , Lu Shun , Shin Sang Won , Yang James Chi-Hsin , Zhang Yiping , Zhao Jun , Berghoff Karin , Bruns Rolf , Johne Andreas , Wu Yi-Long
Published: September 2024

Plain language summary
Supplementary Data 2 from A phase 2 study of epacadostat and pembrolizumab in patients with advanced sarcoma
Authors: Kelly Ciara M. , Qin Li-Xuan , Whiting Karissa A. , Richards Allison L. , Avutu Viswatej , Chan Jason E. , Chi Ping , Dickson Mark A. , Gounder Mrinal M. , Keohan Mary Louise. , Movva Sujana , Nacev Benjamin A. , Rosenbaum Evan , Adamson Travis , Singer Samuel , Bartlett Edmund K. , Crago Aimee M. , Yoon Sam S. , Hwang Sinchun , Erinjeri Joseph P. , Antonescu Cristina R. , Tap William D. , D'Angelo Sandra P.
Published: September 2024

Normalized Tryptophan Concentrate Over Time
Supplementary Table S3 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Authors: Rotow Julia , Patel Jyoti D. , Hanley Matthew P. , Yu Helena , Awad Mark , Goldman Jonathan W. , Nechushtan Hovav , Scheffler Matthias , Kuo Chih-Hsi S. , Rajappa Senthil , Harada Guilherme , Clifford Sarah , Santucci Alison , Silva Laura , Tupper Rebecca , Oxnard Geoffrey R. , Kherani Jennifer , Drilon Alexander
Published: September 2024

Combination therapy dosing
Supplementary Figure S2 from Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
Authors: Rotow Julia , Patel Jyoti D. , Hanley Matthew P. , Yu Helena , Awad Mark , Goldman Jonathan W. , Nechushtan Hovav , Scheffler Matthias , Kuo Chih-Hsi S. , Rajappa Senthil , Harada Guilherme , Clifford Sarah , Santucci Alison , Silva Laura , Tupper Rebecca , Oxnard Geoffrey R. , Kherani Jennifer , Drilon Alexander
Published: September 2024

Durable combination therapy benefit
Supplementary Figure S3 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Authors: Tolmeijer Sofie H. , Boerrigter Emmy , Sumiyoshi Takayuki , Kwan Edmond M. , Ng Sarah , Annala Matti , Donnellan Grainne , Herberts Cameron , Benoist Guillemette E. , Hamberg Paul , Somford Diederik M. , van Oort Inge M. , Schalken Jack A. , Mehra Niven , van Erp Nielka P. , Wyatt Alexander W.
Published: September 2024

Oncoprint showing the copy number alterations, structural variants and mutations per patient at baseline
Supplementary Table S1 from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Kottschade Lisa A. , Pond Gregory Russell. , Olszanski Anthony J. , Zakharia Yousef , Domingo-Musibay Evidio , Hauke Ralph J. , Curti Brendan D. , Schober Sarah , Milhem Mohammed M. , Block Matthew S. , Hieken Tina , McWilliams Robert R.
Published: September 2024

Adverse Events Per Patient
Supplementary Figure S5 from Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients
Authors: Thiesler Hauke , Gretenkort Lina , Hoffmeister Leonie , Albers Iris , Ohlmeier Luisa , Röckle Iris , Verhagen Andrea , Banan Rouzbeh , Köpcke Nora , Krönke Nicole , Feuerhake Friedrich , Behling Felix , Barrantes-Freer Alonso , Mielke Dorothee , Rohde Veit , Hong Bujung , Varki Ajit , Schwabe Kerstin , Krauss Joachim K. , Stadelmann Christine , Hartmann Christian , Hildebrandt Herbert
Published: September 2024

OS analysis of the two GB cohorts individually stratified for CD163 to CD68 or CD74 to IBA1 ratios
Supplementary Methods S1 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Methods, Results, Table of Contents
Supplementary Figures S2 from DNA-Methylome based Tumor Hypoxia Classifier Identifies HPV-negative Head & Neck Cancer Patients at Risk for Locoregional Recurrence After Primary Radiochemotherapy
Authors: Tawk Bouchra , Rein Katrin , Schwager Christian , Knoll Maximilian , Wirkner Ute , Hörner-Rieber Juliane , Liermann Jakob , Kurth Ina , Balermpas Panagiotis , Roedel Claus , Linge Annett , Loeck Steffen , Lohaus Fabian , Tinhofer Ingeborg , Krause Mechthild , Stuschke Martin , Grosu Anca-Ligia , Zips Daniel , Combs Stephanie E. , Belka Claus , Stenzinger Albrecht , Herold-Mende Christel , Baumann Michael , Schirmacher Peter , Debus Jürgen , Abdollahi Amir
Published: September 2024

Supplementary Figure S2. (Top) Hypoxia-M V2 is prognostic in the DKTK-ROG cohort.
Patients predicted to have higher tumor hypoxia by Hypoxia-M V2 had higher rates of death
(p=0.0097), local recurrence (p=0.0037), distant metastasis (p=0.027) and disease
progression (p=0.00096). (Bottom) Hypoxia-M V2 remains an independent prognosticator of
OS, LR and disease progression after adjusting for age, smoking status, GTV and anatomical
site. Additionally, there is a trend towards higher rates of distant metastasis (HR=2.33,
p=0.13)
Supplementary Table S3 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Authors: Leboulleux Sophie , Do Cao Christine , Zerdoud Slimane , Attard Marie , Bournaud Claire , Lacroix Ludovic , Benisvy Danielle , Taïeb David , Bardet Stephane , Terroir-Cassou-Mounat Marie , Anizan Nadege , Bouvier-Morel Emilie , Lamartina Livia , Lion Georges , Betrian Sarah , Sajous Christophe , Schiazza Aurelie , Garcia Marie-Eve , Ciappuccini Renaud , Schlumberger Martin , Al Ghuzlan Abir , Godbert Yann , Borget Isabelle
Published: September 2024

Details of samples available for molecular analysis
Supplementary Table S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer
Authors: Leboulleux Sophie , Do Cao Christine , Zerdoud Slimane , Attard Marie , Bournaud Claire , Lacroix Ludovic , Benisvy Danielle , Taïeb David , Bardet Stephane , Terroir-Cassou-Mounat Marie , Anizan Nadege , Bouvier-Morel Emilie , Lamartina Livia , Lion Georges , Betrian Sarah , Sajous Christophe , Schiazza Aurelie , Garcia Marie-Eve , Ciappuccini Renaud , Schlumberger Martin , Al Ghuzlan Abir , Godbert Yann , Borget Isabelle
Published: September 2024

Protocol inclusion and exclusion criteria
Supplementary Data File 1 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Authors: Kelly William , Diaz Duque Adolfo Enrique , Michalek Joel , Konkel Brandon , Caflisch Laura , Chen Yidong , Pathuri Sarath Chand. , Madhusudanannair Kunnuparampil Vinu , Floyd John , Brenner Andrew
Published: September 2024

Exosome Analysis Summary
Supplemental Table S1 from Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Authors: Kelly William , Diaz Duque Adolfo Enrique , Michalek Joel , Konkel Brandon , Caflisch Laura , Chen Yidong , Pathuri Sarath Chand. , Madhusudanannair Kunnuparampil Vinu , Floyd John , Brenner Andrew
Published: September 2024

Representativeness of Study Participants
Supplementary Table S3 from A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer
Authors: Disis Mary L. , Dang Yushe , Coveler Andrew L. , Childs Jennifer S. , Higgins Doreen M. , Liu Ying , Zhou Jing , Mackay Sean , Salazar Lupe G.
Published: September 2024

Immunologic parameters pre-treatment between PR+SD and PD patients.
Supplementary Table S2 from A Phase I/II trial of HER-2/neu vaccine primed autologous T-cell infusions in patients with treatment refractory HER-2/neu overexpressing breast cancer
Authors: Disis Mary L. , Dang Yushe , Coveler Andrew L. , Childs Jennifer S. , Higgins Doreen M. , Liu Ying , Zhou Jing , Mackay Sean , Salazar Lupe G.
Published: September 2024

Detailed adverse events.
Supplementary Table S1 from First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma
Authors: Duan Xiaojiang , Xia Lei , Zhang Zhuochen , Ren Yanan , Pomper Martin G. , Rowe Steven P. , Li Xuesong , Li Nan , Zhang Ning , Zhu Hua , Yang Zhi , Sheng Xinan , Yang Xing
Published: September 2024

Representativeness of study participants